Cipher Pharma (CPHR) Names Stephen Lemieux as CFO
- Nasdaq, S&P tumble as Netflix, chip stocks drag; AmEx boosts Dow
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Nasdaq tumbles, Treasuries dip amid earnings, geopolitical crosscurrents
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Jabil falls after placing CEO on paid leave amid internal investigation
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
Cipher Pharmaceuticals appoints Stephen Lemieux as Chief Financial Officer
September 1, 2016 5:00 PM EDTCompany also announces appointment of Dr. John Mull as Chair of the Board of Directors
MISSISSAUGA, ON, Sept. 1, 2016 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX: CPH) ("Cipher" or "the Company") today announced that Stephen L. Lemieux, BA, MMPA, CPA, has been appointed Chief Financial Officer and Secretary of the Company, effective September 12, 2016. Mr. Lemieux replaces Norman Evans, who, as previously announced, is retiring after almost 10 years as the Chief Financial Officer of Cipher. Mr. Evans will continue with Cipher in a consulting capacity to... More